MFM Victoria Flores

M Victoria Flores

*This is an algorithmically generated author record based on publicly available information.

M Victoria Flores has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacokinetics and Safety in Cynomolgus Monkeys of a Monoclonal Antibody Targeting Human Scavenger Receptor Class B Type-1 for Hepatitis C Treatment

    by M Victoria Flores, Romuald G Corbau, Silvia Guionaud

    Background: Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential therapeutics for the treatment of HCV infections. The purpose of this study was to evaluate the safety and pharmacokinetics of an anti-hSR-B1 antibody (Seq2) in cynomolgus monkeys. Methods: The antibody was administered intravenously at 1, 10 and 100 mg/kg body weight; blood samples were taken pre- and post-dose to evaluate the pharmacokinetic profile and blood chemistry. Safety was assessed during treatment and the animals were sacrificed post-treatment for pathological assessment and liver antibody-receptor occupancy determination. Results: Following administration of Seq2 antibody to cynomolgus monkeys a non-linear pharmacokinetic pro-file was observed. The clearance of the antibody decreased from 2 to 0.3 ml/h/kg with increasing doses from 1 to 100 mg/kg, respectively, and the antibody half-life varied from 62 to 218 h for the same doses. An increase in total cholesterol and high-density lipoprotein cholesterol levels after antibody administration was observed, with a good correlation between liver receptor occupancy and dose. Conclusions: The pharmacokinetics and toxicology results were in accordance with the pharmacology of the antibody mechanism. The elevation of total cholesterol was dose-dependent and did not exceed a twofold increase. The safety study indicated no adverse effects during the treatment or in the pathology analysis at any of the doses tested.


  • Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV

    by M Victoria Flores, Timothy P Hickling, Sasha Sreckovic, Mark D Fidock, Nigel Horscroft, Madan Katragadda, Boris Savic, Jaiessh Rawal, Oona E Delpuech-Adams, Nicola Robas, et al.

  • Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV

    by M Victoria Flores, Timothy P Hickling, Sasha Sreckovic, Mark D Fidock, Nigel Horscroft, Madan Katragadda, Boris Savic, Jaiessh Rawal, Oona E Delpuech-Adams, Nicola Robas, et al.

    Background: This study presents preclinical data of a novel interferon (IFN)-α8 fusion protein, PF-04849285, and compares it with IFN-α2 and pegylated IFN-α2; the latter being the current standard of care for HCV. Methods: The antiviral properties were evaluated in vitro using the HCV replication assay (replicon) and the general encephalomyocarditis virus assay. The binding affinity to both IFNR-subunits was assessed using surface plasmon resonance. Ex vivo experiments using cynomolgus monkey and human blood were used for the evaluation of induction of IFN-inducible biomarkers (interferon inducible protein 10 [IP-10], 2′-5′-oligoadenylate synthetase [OAS2] and interleukin-6 [IL-6]). The molecule was tested intravenously and subcutaneously in cynomolgus monkey in a single dose study for two weeks at 0.01, 1, 5 and 20 mg/kg. Each route and dose combination was given to a single male animal, blood samples were collected for evaluation of biomarkers and pharmacokinetics. The compound was also tested in cynomolgus monkey in a multiple dose study for four weeks, with a twice-a-week dosing prior to a three-week wash-out period for toxicokinetics, pharmacokinetics, and biomarker evaluation at 20, 50 or 100 mg/kg subcutaneously and 20 mg/kg intravenously. Results: The molecule is 10x more potent than the pegylated IFN-α2a, with potency similar to the unmodified IFN-α2a. No unanticipated findings were observed in cynomolgus monkey when dosed up to 20 mg/kg, >10,000-fold margin over the anticipated efficacious human dose. Conclusions: The biomarker and toxicological findings were consistent with a potent IFN molecule. The potency and pharmacokinetic properties of the molecule are consistent with dosing at least twice daily with the potential for monthly dosing.